Delirium Clinical Trial
— MUSYCOfficial title:
MusiC to Prevent deliriUm During neuroSurgerY: A Single Centered Prospective Randomized Controlled Trial
Rationale: Delirium is a common and severe complication after neurosurgical procedures. Music before, during and after surgical procedures has proven its effectiveness in reducing pain, anxiety, stress and opioid medication in surgical patients. These symptoms belong to the main eliciting factors for developing delirium. Effective preventive therapy for delirium is not available. The investigators hypothesize that music listening, being a sustainable intervention with negligible risk of side effects, can lower delirium incidence among neurosurgical patients, resulting in reduction of in-hospital stays, healthcare costs and post-operative morbidity and mortality. Objective: To assess the effect of peri-operative music on post-operative delirium in patients undergoing a craniotomy. Study design: Single-centre prospective randomized controlled trial. Study population: Adult patients undergoing a craniotomy at the Erasmus MC in Rotterdam. Intervention: Recorded music, with headphones or earphones, before, during and after surgery. Main study parameters/endpoints: Diagnosis of post-operative delirium screened by the DOS score confirmed by the consultant psychiatrist following the DSM-V criteria.
Status | Recruiting |
Enrollment | 189 |
Est. completion date | March 9, 2023 |
Est. primary completion date | July 9, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patients undergoing a craniotomy. 2. Adult patients (cq age =18 years) 3. Sufficient knowledge of the Dutch language to understand the study documents in the judgement of the attending physician or researcher. 4. Provision of written informed consent by patient or legal representative. Exclusion Criteria: 1. Impaired awareness before surgery (i.e. GCS < M6). 2. Planned post-operative ICU admission. 3. Suspected delirium (defined as fluctuating awareness). 4. Current antipsychotic treatment 5. Patients undergoing interventions impeding supply of music (e.g. surgical translabyrinthine approach, awake surgery). 6. Severe bilateral hearing impairment, defined as no verbal communication possible. 7. Current participation in other clinical trials interfering with results. |
Country | Name | City | State |
---|---|---|---|
Netherlands | ErasmusMC | Rotterdam | Zuid-Holland |
Lead Sponsor | Collaborator |
---|---|
Erasmus Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pre-operative anxiety. | Using the VAS-anxiety scale, a 11-numeric scale in which 0 represents no anxiety and 10 represents the worse imaginable anxiety, which is easy to use and highly correlated with the State-Trait Anxiety Inventory (STAI). | Day before surgery only | |
Other | Activation of the parasympathetic nervous system. | Heart rate variability (HRV), the variation in the time interval between adjacent heartbeats, with ECG recordings. | The day of surgery (day 0) before and after surgery | |
Other | Depth of anesthesia with Bispectral Index. | Bispectral Index (BIS) which signal reflects processed brain activity, monitored by EEG and generated into numerical values. The acquired BIS value, ranging from 0 to 100, during anaesthesia provides information about the depth of anaesthesia. BIS-values are not evaluated during surgery but merely used for research purposes. | During surgery | |
Other | Peri-operative medication. | Peri-operative medication use, such as opioids, benzodiazepines and antipsychotic drugs will be extracted from the electronic patient files. Analgesic opioid medica-tion will be converted to milligrams of morphine equivalents, using a conversion tool based on the guidelines by the American Pain Society.61 | During admission. | |
Other | Postoperative pain. | Postoperative pain, assessed using an 11-point NRS-scale, in which 0 implies no pain and 10 the worst pain possible. | Post-operative day 1 - 3 | |
Other | Patients with postoperative complications. | Postoperative complications such as post-operative hemorrhagic, surgical site infection, hydrocephalus, vasospasms, liquor leakage, epilepsy, pulmonary complications, thromboembolic complications, gastro-intestinal complications and urinary tract infections will be extracted from the electronic patient files. Definition of the complication is an adverse event within two weeks after surgery resulting in prolongation of current admission, new treatment (surgery or pharmacological) or death. | Within two weeks after surgery. | |
Other | Hospital length of stay. | Peri-operative length of in-hospital stay in days. | From baseline until discharge in the same admission having received the intervention. | |
Other | Cognitive function. | Cognitive function assessed with the Montreal Cognitive Assessment (MoCA) tool at baseline and during follow-up at 3 and 6 months. The MoCA is a validated 0 to 30 points scoring system involving visuospatial, naming, memory, language, abstraction, delayed recall and orientation. | Baseline, 3 months and 6 months after surgery. | |
Other | Patient functional outcome. | Patient functional outcome expressed in Karnofsky Performance Scale (KPS). The KPS has achieved the reputation of 'gold standard' for the measurement of physical performance in clinical (neuro-) oncology. It consists of 11 categories denoted in deciles from 100 (asymptomatic, normal function) to 0 (death). | Baseline, 6 weeks, 3 months and 6 months. | |
Other | Patient functional outcome. | Patient functional outcome expressed in Modified Ranking Scale (mRS). The mRS is a 7-item scale from 0 (no symptoms) to 6 (dead) and is validated in patient groups with neurological diseases. | Baseline, 6 weeks, 3 months and 6 months. | |
Other | Mortality and readmission rate. | Mortality and readmission rate will be evaluated during the follow-up at 6 weeks, 3 and 6 months. | Follow up until 6 months. | |
Other | Patient reported outcome. | Patient reported outcomes, measured through the questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Cancer (EORTC QLQ-C30). The EORTC QLQ-C30, an approach for evaluating the Health-related quality of life (HRQoL) in international cancer clinical trials, incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). Items are presented as questions on a scale ranging from 1 = "not at all" to 4 = "very much." | Baseline, 6 weeks, 3 months and 6 months after surgery. | |
Other | Patient reported outcome. | Patient reported outcomes, measured through the questionnaire of the European Organization for Research and Treatment of Cancer Quality of Life Brain Neoplasm (EORTC BN-20). The EORTC BN-20, an approach for evaluating the Health-related quality of life (HRQoL) in patients with brain tumours, consists of 20 items that assess future uncertainty, visual disorder, motor dysfunction, and communication deficit. Items are presented as questions on a scale ranging from 1 = "not at all" to 4 = "very much." | Baseline, 6 weeks, 3 months and 6 months after surgery. | |
Other | Patient reported outcome. | Patient reported outcomes, measured through the EuroQol-5D (EQ-5D) questionnaire. The EQ-5D-3L, an approach for evaluating the Health-related quality of life (HRQoL) in patients, comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, moderate problems and extreme problems | Baseline, 6 weeks, 3 months and 6 months after surgery. | |
Other | Patient satisfaction. | Patient satisfaction of music around operations will be measured through a Visual Analogue Scale: a line of 10 centimeters in length with "not satisfied at all" and "very satisfied" at the left and right extremes respectively. | Follow-up 6 weeks | |
Other | Economic evaluation. | Productivity losses will be measured and valued using the iMTA Productivity Cost Questionnaire (iPCQ) collected at 3 and 6 months. The iPCQ includes three modules measuring productivity losses of paid work due to 1) absenteeism and 2) presenteeism and productivity losses related to 3) unpaid work. | Follow-up at 3 and 6 months | |
Primary | Delirium | All participating patients on the ward will be screened using the Delirium Observation Screening (DOS) scale. The DOS is a score of 1 until 13, in which a score of 3 or higher is suspicious for delirium. Screening is conducted 3 times per day (i.e. during each shift) and maintained until day 5. In case of raised suspicion of delirium by DOS, a psychiatrist is consulted to confirm or reject clinical diagnosis of delirium based on the DSM-V criteria. Presence of delirium is confirmed by the psychiatrist after positive DOS screening, all other patients will be considered as absence of delirium. In case of discharge towards another hospital within 5 days, onset of delirium is evaluated in that hospital. In case of discharge within 5 days towards home without delirium, it will be considered as no delirium. | First five post-operative days. In case of discharge within 5 days towards home without delirium, it will be considered as no delirium. | |
Secondary | Severity and duration of delirium. | In case of positive delirium, its severity will be assessed using the Delirium Rating Scale-revised-98 (DRS-R-98). DSR-98 regards a 13-item score sheet in which 0 represents the lowest and 39 represents the highest severity. It will be assessed by the consultant psychiatrist on the day of onset of delirium. Subsequently, as long as the delirium lasts the severity is assessed once every three days (i.e. Monday, Wednesday and Friday). To assess duration of delirium, the DOS score will be used; a DOS <3 during 24 hours will be considered as a 'faded out' delirium and number of days from onset until end will be documented. | First five days or discharge. In case of positive delirium until it has 'faded out'. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04551508 -
Delirium Screening 3 Methods Study
|
||
Recruiting |
NCT05891873 -
Delirium in the (Neuro)Intensive/Critical Care in the Adult and Paediatric Czech Populations
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Recruiting |
NCT06194474 -
Study on Biomarkers of Postoperative Delirium in Elderly Cardiac Surgery Patients
|
||
Completed |
NCT03095417 -
Improving the Recovery and Outcome Every Day After the ICU
|
N/A | |
Completed |
NCT05395559 -
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
|
||
Terminated |
NCT03337282 -
Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
|
||
Not yet recruiting |
NCT04846023 -
Pediatric Delirium Screening in the PICU Via EEG
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Withdrawn |
NCT02673450 -
PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.
|
||
Recruiting |
NCT03256500 -
Transcranial Direct Current Stimulation for the Treatment of Delirium
|
N/A | |
Not yet recruiting |
NCT02892968 -
ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients
|
N/A | |
Completed |
NCT02890927 -
Geriatric-CO-mAnagement for Cardiology Patients in the Hospital
|
N/A | |
Recruiting |
NCT03165539 -
Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients
|
||
Completed |
NCT02518646 -
DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models
|
N/A | |
Completed |
NCT02554253 -
The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction
|
Phase 2 | |
Recruiting |
NCT02305589 -
The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium
|
N/A | |
Completed |
NCT02628925 -
Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale
|
N/A |